Clot waveform analysis in patients with haemophilia A

Size: px
Start display at page:

Download "Clot waveform analysis in patients with haemophilia A"

Transcription

1 Original article S Clot waveform analysis in patients with haemophilia A T. Siegemund 1 ; U. Scholz 2 ; R. Schobess 2 ; A. Siegemund 2 1 The Scripps Research Institute, Department of Molecular and Experimental Medicine, Roon Research Center for Arteriosclerosis and Thrombosis, La Jolla, California, USA; 2 MVZ Lab Dr. Reising-Ackermann and Colleagues, Center of Coagulation Disorders, Leipzig, Germany Keywords Activated partial thromboplastin time, fibrin formation kinetics, thrombin, prothrombinase, tenase, haemophilia Summary Clot waveform analysis extends the interpretation of aptt measurement curves. The curve is mathematically processed to obtain information about fibrin formation kinetics including semiquantitative determination of thrombin, prothrombinase and tenase activity. Patients, method: In this study the feasibility of clot waveform analysis for monitoring of haemophilia A was investigated using blood samples from healthy controls as well as haemophilia A patients under various clinical conditions. Results: Thrombin, prothrombinase and tenase activity show a high correlation to factor VIII levels. Tenase activity was found to exhibit a linear relationship to factor VIII levels over a very large concentration range and was able to discriminate patients with severe, moderate and mild haemophilia. Conclusion: Clot waveform analysis is an easy, fast and cheap method to access disturbances in clot formation and can be done without any additional measurements beside an aptt. Correspondence to: T. Siegemund MVZ Lab Dr. Reising-Ackermann and Colleagues Center of Coagulation Disorders Strümpellstr., 29 Leipzig, Germany Schlüsselwörter Aktivierte partielle Thromboplastinzeit, Fibrin bildungskinetik, Thrombin, Prothrombinase, Tenase, Hämophilie Zusammenfassung Clot-Waveform-Analyse leitet zusätzlich Daten aus aptt-messungen aus. Die aufgezeichnete Messkurve wird mathematisch aufbereitet und die Kinetik der Fibrinbildung einschließlich Thrombin-, Prothrombinaseund Tenaseaktivität semiquantitativ bestimmt. Patienten, Methode: Proben gesunder Blutspender als auch von Hämophilie- A-Patienten in verschiedenen klinischen Situationen wurden untersucht, um die Anwendbarkeit der Clot-Waveform-Analyse für die Überwachung der Hämophilie A zu prüfen. Ergebnisse: Thrombin-, Prothrombinaseund Tenaseaktivität zeigen eine hohe Korrelation zum Faktor- VIII-Spiegel. Ein linearer Zusammenhang wurde zwischen Tenaseaktivität und Faktor VIII-Spiegel über einen großen Konzentrationsbereich gefunden. Patienten mit schwerer, moderater oder milder Hämophilie können gut diskriminiert werden. Schlusssfolgerung: Clot-Waveform-Analyse ist eine einfache, schnelle und preiswerte Methode, um Störungen der Fibrinbildung zu untersuchen. Die Daten können aus einer aptt-bestimmung gewonnen werden. Clot-Waveform-Analyse bei Patienten mit Hämophilie A Haemostaseologie Supplement 21; 3: S S62 received: February 2, 21 accepted in revised form: October, 21 An expanded interpretation of optical data retrieved during clot formation in measurements of activated partial thromboplastin time (aptt) or prothrombin time (PT) was proposed to provide additional information about coagulation disorders (1). Using transmittance data from aptt measurements an improved classification of factor VIII (FVIII) deficiency at levels less than.1 U ml 1 was achieved (2). This approach, called clot waveform analysis, also allowed monitoring of FVIII substitution therapy in patients with high responding inhibitors (3). On the other hand, a biphasic waveform caused by formation of a complex of C-reactive protein and very-low-density lipoprotein is an indicator for disseminated intravascular coagulation and the degree of waveform abnormality correlates with the severity of haemostatic dysfunction (). The inability to create sufficient amounts of activated factor X is a hallmark of haemophilia (). Subsequently, the amount and velocity of thrombin and fibrin formation is diminished (6). Extending the analysis of clot formation kinetics beyond the first appearance of fibrin poses a promising tool in diagnosis and monitoring of haemophilia. Compared to thrombin generation assays, clot waveform analysis is performed at a fraction of effort and cost. On the other hand, measuring absorbance excludes the use of platelet-rich plasma or whole blood. Technical background Considering basic physico-chemical principles, the method may provide additional information about coagulation disorders. By using an optical detection system, alteration of absorbance (or transmission) (1 ) during clot formation can be related Schattauer 21 Hämostaseologie a/21 Downloaded from on IP:

2 S9 T. Siegemund et al.: Clot waveform analysis Fig. 1 Clot waveform analysis interprets the time course on optical data obtained during fibrin formation in the coagulation process by calculating derivatives of the measured curve (actual sample). The y-axis exhibits a nonlinear scale. Absorbance da/dt d 2 A/dt 2 d 3 A/dt 3 to fibrin concentration, and to some extent to fiber thickness (7), similar to the Beer- Lambert law (the Beer-Lambert law does not apply when light is scattered within the sample; nevertheless, attenuation of light time (s) due to scattering follows a similar relationship in respect to the concentration). The subsequent derivatives of the measured curve with respect to time can be related to fibrin formation properties through Michaelis-Menten kinetics ( Tab. 1, Fig. 1). Measured data are processed mathematically to obtain information regarding fibrin formation (measured curve), thrombin activity (1 st derivative), prothrombinase activity (2 nd derivative) and tenase activity (3 rd derivative). The use of the first derivative to calculate thrombin activity is already used in thrombin generation assays where an artificial substrate is used instead of the natural substrate fibrinogen. Using the same rationale, prothrombin can be seen as the substrate and prothrombinase as the enzyme. The first derivative of the thrombin activity in respect to time, which is the same as the second derivative of the fibrin formation curve, leads to prothrombinase activity. Similar, the third derivative leads to tenase activity. This approach is the reversal of calculating fibrin formation from systems of differential equations represent- Thrombin (nm) Thrombin 1 st derivative st derivative da (dt) tenase activity (1 3 s 3 ) 2 3 rd derivative y = 1.39x.272 R 2 = time (s) Fibrinogen (g l 1 ) thrombin activity (1 3 s 1 ) 2 1 st derivative normalized R 2 =.91 tenase activity (1 3 s 3 ) rd derivative (normalized) y =.9x R 2 = thrombin concentration (nm) Fig. 2 Comparison between 1 st derivative of the normalized fibrin formation curve and the thrombin activity (calculation according to Materials and Methods). Time course of 1 st derivative and thrombin activity for a representative sample (left) and correlation between both parameters in samples from this study (right) Fibrinogen (g l 1 ) Fig. 3 The strong correlation between all clot waveform analysis parameters (top, exemplary tenase activity, 3 rd derivative) and fibrinogen levels is eliminated upon normalization (bottom) of the underlying measured curve. Hämostaseologie a/21 Schattauer 21 Downloaded from on IP:

3 T. Siegemund et al.: Clot waveform analysis S ing the waterfall sequence of the coagulation system (, 9). As all those processes depend on the concentration of the involved reaction partners and their mutual affinities, the data only represent semi-quantitative measurements. Furthermore, the consumption of reaction partners and substrates allows data interpretation only within the first phase of the coagulation process. thrombin activity (1 3 s 1 ) prothrombinase activity (1 3 s 2 ) tenase activity (1 3 s 3 ) st derivative (normalized) Patients, material, methods All patients and controls were from our Center of Coagulation Disorders at the MVZ Lab Dr. Reising-Ackermann and Colleagues. Specimens were obtained after informed consent in accordance to the Declaration of Helsinki. The measurements were performed on the fully automated ACL TOP (Instrumentation Laboratory, Munich, Germany). R 2 = nd derivative (normalized) 3 rd derivative (normalized) R 2 =.23 R 2 = Fig. Increasing linearity in the relationship between fviii levels and clot waveform analysis parameters with higher derivates of the measured curve. The maxima of the 1 st derivative (top, re - presenting thrombin activity), 2 nd derivative (middle, prothrombinase activity) and 3 rd derivative (bottom, tenase activity) were determined after normalization of the underlying measured curve. Synthasil (Instrumentation Laboratory), an aptt reagent containing synthetic phospholipids, was used to activate the intrinsic coagulation cascade. Data of the measured curves were exported into a spreadsheet and derivatives were calculated according to the Savitzky-Golay algorithm (1) using Microsoft Excel (the algorithm was performed using a 3 rd degree polynomial comprising 2 data points). Thrombin activity was alternatively calculated as published by Rand (11) using reaction constant as published by Higgins () assuming 9% consumption of fibrinogen and compared to values of the 1 st derivative. da/dt [Fibrin(t)] + k Thrombin (t) = ( 1 + M [Fibringogen(t)] ) k cat Total change in absorbance of each reaction curve is normalized to a fixed absorbance change (1 x 1 3 absorbance units). For normalized data, curves with incomplete fibrin formation (absorbance is still changing at the end of the measurement) may be excluded from further analysis. Clot waveform analysis parameters reflect the maxima of each derivative. A software (Borland Delphi) was developed to expedite data analysis. FVIII was determined using a one-stage assay (Instrumentation Laboratory) or a chromogenic two-stage assay (Siemens Healthcare Diagnostics, Marburg, Germany). Results The concept of clot waveform analysis was tested in patients and controls. The 1 st derivative, representing thrombin activity showed a very high correlation (r 2 =.9, Fig. 2) with the actual thrombin activity using a modified Michaelis-Menten equation including substrate inhibition. Similar comparisons between 2 nd derivative and prothrombinase activity was not performed, as too many unknown variables are involved (e. g. free factor Xa or degree of factor Xa consumption). The appearance of negative values in the 2 nd and 3 rd derivative due to inhibition (e. g. antithrombin, activated protein C) and substrate consumption make the calculations require a high number of assumptions. Furthermore, the Schattauer 21 Hämostaseologie a/21 Downloaded from on IP:

4 S1 T. Siegemund et al.: Clot waveform analysis assay is unable to differentiate between intrinsic and extrinsic tenase. All investigated clot waveform analysis parameters show a significant correlation with fibrinogen levels that is completely eliminated upon normalization ( Fig. 3). Constant absorbance at the end of the measured curve is mandatory, otherwise normalization leads to overestimated values for the subsequent derivatives. Patients with haemophilia A show significantly impaired fibrin formation in clot waveform analysis. Severe haemophilia A exhibits a delayed begin of clotting, thrombin, prothrombinase and tenase activity are extremely low or not detectable. A significant improvement of clot waveform analysis parameters was found in samples from patients with moderate or mild haemophilia. The four patients with the lowest FVIII levels (around.1 U ml 1 ) showed the lowest values in the 3 rd derivative of clot waveform analysis. The maxima of all derivatives show a high positive correlation with FVIII levels over a wide concentration range ( Fig. ). While a logarithmic relationship is observed between FVIII level determined in the onestage assay and the maximum thrombin activity (1 st derivative), it becomes increasingly linear for prothrombinase activity (2 nd derivative) and tenase activity (3 rd derivative) as seen by increased correlation coefficients for a linear model. Similar results were obtained in comparison to the two-stage assay (data not shown). FVIII substitution therapy was monitored in a patient undergoing surgery at 1 different time points. An almost identical time course of FVIII levels and tenase activity determined by clot waveform analysis was observed ( Fig. ). FVIII recovery was monitored in 11 patients. Prothrombinase activity and even more tenase activity showed good correlation with the increase of FVIII activity ( Fig. ). Discussion In this study, the feasibility of clot waveform analysis for monitoring of haemophilia A patients was investigated. The para - meters determined by the method correlate well with conventionally determined FVIII levels over a wide concentration range. Fig. High correlation between fviii levels and tenase activity determined by clot waveform analysis (3 rd derivative). Time course of fviii levels and clot waveform analysis in a haemo - philia A patient under fviii substitution undergoing surgery (top); simultaneous increase of fviii levels, tenase activity and prothrombinase activity in different patients after fviii substitution. relative increase after substitution rd derivative.6 (normalized) Even at very low levels of FVIII clot waveform analysis showed a very good discrimination between samples with small differences in FVIII levels, a phenomenon that was previously described by Shima (2). This study expands the analysis of aptt measurements to the third derivative, assumed to represent tenase activity. The linear relationship between FVIII levels and the obtained tenase activity supports the validity of the presented approach. Although slightly lower correlation is observed between FVIII levels and prothrombinase activity or thrombin activity, the method underlines that haemophilia leads to a delayed and diminished generation of factor Xa and thrombin, respectively. It could be shown that the 1 st derivative correlates well with the actual thrombin concentration obtained by an advanced mathematical model (11, ). For the subsequent derivatives such a model would contain too many assumptions to yield a reliable comparison. The total absorbance change, and subsequently, the maxima of all derivatives of the 1 fator VIII tenase activity t1 t2 t3 t t t6 t7 t t9 t1 t11 t t13 t1 t1 blood sample prothrombinase activity tenase activity f VIII p1 p2 p3 p p p6 p7 p p9 p1 p11 tenase activity (1 3 s 3 ) measured curve strongly depend on the fibrinogen level in the sample. Normalization is shown to eliminate this effect and leads to a significantly improved correlation of all determined parameters to FVIII. On the other hand, fibrinogen is the natural substrate of the coagulation cascade and has itself a significant influence on clot formation in vitro and in vivo. Further studies may show, whether inclusion or exclusion of fibrinogen provides better information about a patients coagulation state. It is noteworthy, that clot waveform analysis is unable to discriminate between FVIII and FIX deficiencies. Furthermore, this study did not include patients with defects in other coagulation factors than FVIII. As the method uses absorption measurements for the determination of fibrin formation, platelet rich plasma or whole blood can not be used as a specimen. On the other hand, applying clot waveform analysis on thrombin generation measurement curves is conceivable. Alterations of plasma that interfere with aptt or absorb- Hämostaseologie a/21 Schattauer 21 Downloaded from on IP:

5 T. Siegemund et al.: Clot waveform analysis S2 ance measurements in general, like inflammation, high CRP-levels, haemolysis, extreme haematocrit values, high lipid or bilirubin levels were not investigated. Whether clot waveform analysis is superior to the direct determination of FVIII levels for the prediction of bleeding remains an open question and must be proven by including clinical data. The low technical effort makes it a promising monitoring tool in haemophilia treatment and might also allow retrospective analysis of already obtained data. While the measurement of FVIII requires some technical and financial effort and is not available in all places at all times, an aptt measurement itself requires significantly less efforts. In what extend, clot waveform analysis can compete with or add to thrombin generation measurements in the understanding of clot formation remains an interesting question. Conclusion Clot waveform analysis is an easy, fast and cheap method to access disturbances in clot formation. It requires continuous monitoring of absorbance changes during an aptt measurement and can be performed on most of the modern coagulation analyzers, although additional software is required. The analysis itself is performed using a simple and fast mathematical approach, reducing the required technical effort to a minimum. Conflict of interest The authors declared that they have no conflict of interest. References 1. Braun PJ, Givens TB, Stead AG et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 7: Shima M, Matsumoto T, Fukuda K et al. The utility of activated partial thromboplastin time (aptt) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 22; 7: Kasuda S, Tanaka I, Shima M et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia 2; 1: Toh CH, Samis J, Downey C et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca ++ -dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 22; 1: Hoffman M, Monroe DM 3 rd. A cell-based model of hemostasis. Thromb Haemost 21; : Siegemund T, Petros S, Siegemund A et al. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 23; 9: Wolberg AS, Gabriel DA, Hoffman M. Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinol 22; 13: Chatterjee MS, Denney WS, Jing H, Diamond SL. Systems biology of coagulation initiation: kinetics of thrombin generation in resting and activated human blood. PLoS Comput Biol 21; Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 22; 277: Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 196; 36: Rand MD, Lock JB, van t Veer C et al. Blood clotting in minimally altered whole blood. Blood 1996; : Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J Biol Chem 193; 2: Appendix Calculation The Michaelis-Menten equation for the cleavage of a substrate S The reaction velocity v is given by the first derivative of the substrate concentration S in respect to time t v = d[s] / dt The maximal reaction velocity v max is given by the enzyme concentration and the k cat v max = [E] k cat Therefore, As we observe the generation of the product P (fibrin) instead the cleavage of the substrate S (fibrinogen) we write d[s] / dt = d[p] / dt The change of the product concentration d[p]/d[t] is observed measuring absorbance change d[a]/d[t] (similar to Lambert-Beer) which is the first derivative of the measured curve d[p] / dt = d[a] / dt d ε Finally we get Rearranged the enzyme concentration E is given by If the substrate concentration S exceeds k m or the change of the substrate concentration S is insignificant ([S] + k m ) / [S] is considered constant. All constant values are combined [E] = k total d[a] / dt or [E] ~ d[a] / dt (semiquantitative) Now we can calculate (estimate) a thrombin generation curve from the fibrin generation curve (similar to thrombin generation where a fluorogenic substrate is measured instead of fibrin) by calculating the first derivative of the absorbance (fibrin formation) curve. In a similar way Xa generation is calculated as the first derivative of the now calculated thrombin generation curve which is the second derivative of the fibrin formation curve. Tenase activity is the first derivative of Xa activity, the second derivative of thrombin activity and the third derivative of fibrin concentration at any time point. From this method it is impossible to distinguish between extrinsic and intrinsic tenase. Schattauer 21 Hämostaseologie a/21 Downloaded from on IP:

Beyond Clotting Time Clot Waveform Analysis (CWA)

Beyond Clotting Time Clot Waveform Analysis (CWA) Beyond Clotting Time Clot Waveform Analysis (CWA) DR CHUEN WEN TAN CONSULTANT DEPARTMENT OF HAEMATOLOGY SINGAPORE GENERAL HOSPITAL FELLOW ANZAC RESEARCH INSTITUTE HAEMATOLOGY, CONCORD HOSPITAL Outline

More information

EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION

EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE

More information

Insights on the Quality of Coagulation Testing

Insights on the Quality of Coagulation Testing Insights on the Quality of Coagulation Testing Piet Meijer ECAT Foundation The Netherlands No conflicts of interest HAEMOSTATIC BALANCE BLEEDING HAEMOSTATIC BALANCE THROMBOSIS HAEMOSTATIC BALANCE Thrombosis

More information

Primary Exam Physiology lecture 5. Haemostasis

Primary Exam Physiology lecture 5. Haemostasis Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation

More information

Introduction to coagulation and laboratory tests

Introduction to coagulation and laboratory tests Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises

More information

Biochemical Reaction Networks and Blood Clotting

Biochemical Reaction Networks and Blood Clotting Biochemical Reaction Networks and Blood Clotting Yasmeen Hussain, Aaron Fogelson Abstract Following an injury to the walls of a blood vessel, platelet aggregation and blood coagulation are induced. Through

More information

Blood products and plasma substitutes

Blood products and plasma substitutes Blood products and plasma substitutes Plasma substitutes Dextran 70 and polygeline are macromolecular substances which are metabolized slowly; they may be used to expand and maintain blood volume in shock

More information

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th ) Blood coagulation and fibrinolysis Blood clotting (HAP unit 5 th ) Vessel injury Antithrombogenic (Favors fluid blood) Thrombogenic (Favors clotting) 3 Major systems involved Vessel wall Endothelium ECM

More information

Desmopressin testing in haemo - philia A patients and carriers Results of a multi centre survey

Desmopressin testing in haemo - philia A patients and carriers Results of a multi centre survey Original article Schattauer 202 27 Desmopressin testing in haemo - philia A patients and carriers Results of a multi centre survey R. Knöfler ; J. Koscielny 2 ; J. T. Tauer ; B. Huhn ; A. Gneuss ; E. Kuhlisch

More information

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University

More information

Collection of Blood Specimens by Venipuncture for Plasma-Based Coagulation Assays Necessity of a Discard Tube

Collection of Blood Specimens by Venipuncture for Plasma-Based Coagulation Assays Necessity of a Discard Tube Coagulation and Transfusion Medicine / Discard Tube Unnecessary for Coagulation Assays Collection of Blood Specimens by Venipuncture for Plasma-Based Coagulation Assays Necessity of a Discard Tube Maarten

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Shima M, Hanabusa H, Taki M, et al. Factor VIII mimetic function

More information

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the

More information

Determination of APTT factor sensitivity the misguiding guideline

Determination of APTT factor sensitivity the misguiding guideline International Journal of Laboratory Hematology ORIGINAL ARTICLE The Official journal of the International Society for Laboratory Hematology INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Determination

More information

On a Minimal Mathematical Model for Regulation of Factor Va by Activated Protein C

On a Minimal Mathematical Model for Regulation of Factor Va by Activated Protein C UNIVERSITY OF VERMONT DEPARTMENT OF MATHEMATICS AND STATISTICS On a Minimal Mathematical Model for Regulation of Factor Va by Activated Protein C Laura B. Balzer Advisor: Daniel Bentil, Ph.D. Please Note:

More information

THE fundamental concepts of blood coagulation formulated almost 50 years

THE fundamental concepts of blood coagulation formulated almost 50 years NEWER CONCEPTS OF BLOOD COAGULATION ARTHUR L. SCHERBEL, M.D., M.S. in Medicine Department of Medicine THE fundamental concepts of blood coagulation formulated almost 50 years ago by Morawitz 1 have not

More information

Comparison of Three Methods for Measuring Factor VIII Levels in Plasma

Comparison of Three Methods for Measuring Factor VIII Levels in Plasma Coagulation and Transfusion Medicine / THREE FACTOR VIII ASSAYS Comparison of Three Methods for Measuring Factor VIII Levels in Plasma Wayne L. Chandler, MD, Chris Ferrell, MT(ASCP), Joo Lee, MT(ASCP),

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02) European Medicines Agency Human Medicines Evaluation Unit London, 21 October 2004 Corrigendum, 18 November 2004 CPMP/BPWG/3735/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN

More information

Coagulation, Haemostasis and interpretation of Coagulation tests

Coagulation, Haemostasis and interpretation of Coagulation tests Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect

More information

Chapter 1 Introduction

Chapter 1 Introduction Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep

More information

Human coagulation factor Xa, FXa ELISA Kit

Human coagulation factor Xa, FXa ELISA Kit Human coagulation factor Xa, FXa ELISA Kit Catalog No: E1613h 96 Tests Operating instruction www.eiaab.com FOR RESEARCH USE ONLY; NOT FOR THERAPEUTIC OR DIAGNOSTIC APPLICATIONS! PLEASE READ THROUGH ENTIRE

More information

Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test.

Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test. Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test. In the US, the product is intended For Research Use Only.

More information

This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion

This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms

More information

PICT ANTICOAGULANT MONITORING 1. PEFAKIT PICT. Clotting Assay. PEFAKIT PiCT. PEFAKIT PICT Calibrators UFH. PEFAKIT PICT Controls UFH

PICT ANTICOAGULANT MONITORING 1. PEFAKIT PICT. Clotting Assay. PEFAKIT PiCT. PEFAKIT PICT Calibrators UFH. PEFAKIT PICT Controls UFH 1 2 3 4 PEFAKIT PiCT PEFAKIT PICT Calibrators UFH PEFAKIT PICT Controls UFH PEFAKIT PICT Calibrators LMWH Clotting Assay PICT 1. PEFAKIT PICT Package size 8-505-01 kit 80 3 vials of PiCT Activator (2mL)

More information

ACQUIRED COAGULATION ABNORMALITIES

ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation

More information

NOACS/DOACS*: COAGULATION TESTS

NOACS/DOACS*: COAGULATION TESTS NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international

More information

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.

More information

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Internal Quality Control in the Haemostasis laboratory Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Why do we need Quality control? Philadelphia Enquirer Aug

More information

Patients with isolated prolonged in vitro bleeding time Clinical symptoms

Patients with isolated prolonged in vitro bleeding time Clinical symptoms S64 Schattauer 2011 Original article Patients with isolated prolonged in vitro bleeding time Clinical symptoms S. Alesci; M. Stein; K. Scholz; B. Llugaliu; G. Asmelash; W. Miesbach Haemophilia Center,

More information

Topics of today lectures: Hemostasis

Topics of today lectures: Hemostasis Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms of hemostasis - Vascular contraction - Platelets plug - Blood coagulation (clotting) - Structure and functions of platelets - Blood

More information

P re-analytical conditions are very important in laboratory assessment of hemostatic and coagulation systems

P re-analytical conditions are very important in laboratory assessment of hemostatic and coagulation systems OPEN SUBJECT AREAS: PRE-CLINICAL STUDIES PROTEASES BIOCHEMICAL ASSAYS BIOPHYSICAL CHEMISTRY Received 19 November 2013 Accepted 8 January 2014 Published 27 January 2014 Correspondence and requests for materials

More information

PHASES OF HAEMOSTASIS

PHASES OF HAEMOSTASIS HAEMOSTASIS Maintains the integrity of a closed, highpressure circulatory system after vascular damage Vessel Wall Injury events in the vessel wall and in the blood which seal breach Delicate balance exists

More information

Infections, inflammation and venous thrombosis; an epidemiological perspective Tichelaar, Ynse

Infections, inflammation and venous thrombosis; an epidemiological perspective Tichelaar, Ynse University of Groningen Infections, inflammation and venous thrombosis; an epidemiological perspective Tichelaar, Ynse IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)

More information

The LaboratoryMatters

The LaboratoryMatters Laboratory Medicine Newsletter for clinicians, pathologists & clinical laboratory technologists. A Initiative. HEMOSTASIS AND THE LABORATORY This issue highlights: Primary Hemostasis Screening Tests Case

More information

Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used in Coagulation Testing

Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used in Coagulation Testing Coagulation and Transfusion Medicine / GLASS VS PLASTIC IN HEMOSTASIS TESTING Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used

More information

Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin*

Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin* THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 270, No. 43, Issue of October 27, pp. 25383 25387, 1995 1995 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A. Mathematical

More information

Factor VIII Inhibitor Testing: Nijmegen Modifications, Experience and Recommendations

Factor VIII Inhibitor Testing: Nijmegen Modifications, Experience and Recommendations Factor VIII Inhibitor Testing: Nijmegen Modifications, Experience and Recommendations Bert Verbruggen Radboud University Nijmegen Medical Centre The Netherlands 2-12-2008 DISCLOSURE None 2-12-2008 2 ECAT

More information

ab Factor Xa Activity Assay Kit (Fluorometric)

ab Factor Xa Activity Assay Kit (Fluorometric) ab204711 Factor Xa Activity Assay Kit (Fluorometric) Instructions for Use For rapid, sensitive and accurate detection of Factor Xa activity. This product is for research use only and is not intended for

More information

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University In The Name God Coagulation an Overview Dr.Abdolreza Afrasiabi Thalassemia & Heamophilia Genetic Research hcenter Shiraz Medical University Bleeding Clotting Hemostasis Review of platelet function Platelets

More information

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.

More information

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013 General approach to the investigation of haemostasis Jan Gert Nel Dept. of Haematology University of Pretoria 2013 Clinical reasons to investigate haemostasis Investigating a clinically suspected bleeding

More information

SYNOPSIS Prothrombin, both by a one- and a two-stage method, and progressive

SYNOPSIS Prothrombin, both by a one- and a two-stage method, and progressive J. clin. Path., 197, 23, 291-295 Estimation of prothrombin in liver disease P. M. MANNUCCI From the University Institute of Medical Pathology, Ospedale Policlinico, Milan, Italy SYNOPSIS Prothrombin, both

More information

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Bleeding Disorders Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Normal hemostasis The normal hemostatic response involves interactions among: The blood vessel wall (endothelium)

More information

Modeling of human factor Va inactivation by activated protein C

Modeling of human factor Va inactivation by activated protein C Bravo et al. BMC Systems Biology 2012, 6:45 RESEARCH ARTICLE Modeling of human factor Va inactivation by activated protein C Maria Cristina Bravo 1, Thomas Orfeo 2, Kenneth G Mann 2 and Stephen J Everse

More information

COPYRIGHTED MATERIAL. Overview of h emostasis. Kathleen Brummel Ziedins and Kenneth G. Mann University of Vermont, College of Medicine, VT, USA

COPYRIGHTED MATERIAL. Overview of h emostasis. Kathleen Brummel Ziedins and Kenneth G. Mann University of Vermont, College of Medicine, VT, USA 1 Overview of h emostasis Kathleen Brummel Ziedins and Kenneth G. Mann University of Vermont, College of Medicine, VT, USA Introduction The maintenance of blood fluidity and protection from blood leakage

More information

UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.

UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc. UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood

More information

Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.

Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus. Blood clotting It is the conversion, catalyzed by thrombin, of the soluble plasma protein fibrinogen (factor I) into polymeric fibrin, which is deposited as a fibrous network in the primary thrombus. Thrombin

More information

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Part IV Antithrombotics, Anticoagulants and Fibrinolytics Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System

More information

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures

More information

BLEEDING DISORDERS Simple complement:

BLEEDING DISORDERS Simple complement: BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder

More information

CME/SAM. Influence of Coagulation and Anticoagulant Factors on Global Coagulation Assays in Healthy Adults

CME/SAM. Influence of Coagulation and Anticoagulant Factors on Global Coagulation Assays in Healthy Adults Coagulation and Transfusion Medicine / Global Coagulation Assays and Coagulation Proteins Influence of Coagulation and Anticoagulant Factors on Global Coagulation Assays in Healthy Adults Seon Young Kim,

More information

Accepted: 12 November 2018

Accepted: 12 November 2018 Received: 2 August 2018 Revised: 12 November 2018 Accepted: 12 November 2018 DOI: 10.1111/hae.13656 ORIGINAL ARTICLE Laboratory science Accurate measurement of extended half life and unmodified factor

More information

Clinical Overview of Coagulation Testing Issues

Clinical Overview of Coagulation Testing Issues Clinical Overview of Coagulation Testing Issues Adam M. Vogel, MD Assistant Professor, Division of Pediatric Surgery Washington University in St. Louis School of Medicine September 19, 2014 Disclosure

More information

Hemostasis and. Blood Coagulation

Hemostasis and. Blood Coagulation Hemostasis and Blood Coagulation Events in Hemostasis The term hemostasis means prevention of blood loss. Whenever a vessel is severed or ruptured, hemostasis is achieved by several mechanisms: (1) vascular

More information

V. LAB REPORT. PART I. ICP-AES (section IVA)

V. LAB REPORT. PART I. ICP-AES (section IVA) CH 461 & CH 461H 20 V. LAB REPORT The lab report should include an abstract and responses to the following items. All materials should be submitted by each individual, not one copy for the group. The goal

More information

Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department

Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC, consumptive coagulopathy) is a clinicopathologic

More information

I will not discuss off label use or investigational use in my presentation. Consultant for: Astra Zeneca, BayerHealthcare, Boehringer Ingelheim,

I will not discuss off label use or investigational use in my presentation. Consultant for: Astra Zeneca, BayerHealthcare, Boehringer Ingelheim, I will not discuss off label use or investigational use in my presentation. Consultant for: Astra Zeneca, BayerHealthcare, Boehringer Ingelheim, Daiichi- Sankyo, Lilly, Sanofi-Aventis Honoraria from: Astra

More information

Chapter 1. General introduction

Chapter 1. General introduction Chapter 1 General introduction 8 Haemostasis All organs and tissues of higher organisms are provided with nutrients and oxygen through the bloodstream. The bloodstream is an extensive vascular system that

More information

New Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK

New Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK New Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK Ideal Anticoagulant (Hirsh et al 2004) High efficacy to safety ratio Predictable dose response

More information

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels

More information

Worldwide Report Coagulation Lot Exp 31 Oct 2018

Worldwide Report Coagulation Lot Exp 31 Oct 2018 April 0 Worldwide Report Coagulation Lot 780 Exp Oct 08 Activated Partial Thromboplastin Time (APTT) Diagnostica Stago C.K. Prest Seconds 0.7 0.89.8 9 0.7 0.89.8 9 8.8..7 8.8..7 9.90 0.97.0 9.90 0.97.0

More information

Recent experimental and clinical studies have shown that

Recent experimental and clinical studies have shown that Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects Philip W. Friederich, MD; Marcel Levi, MD; Kenneth A. Bauer, MD; George P. Vlasuk, PhD; William

More information

Prothrombin Complex Concentrate- Octaplex. Octaplex

Prothrombin Complex Concentrate- Octaplex. Octaplex Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation

More information

Step 2. Common Blood Tests, and the Coulter Counter Readout

Step 2. Common Blood Tests, and the Coulter Counter Readout Step 2. Common Blood Tests, and the Coulter Counter Readout We will be learning about some common blood tests. We will not be preforming most of them in lab. The student should know their names, their

More information

The information contained here may be very important to your practice. Please take a moment to review this document.

The information contained here may be very important to your practice. Please take a moment to review this document. September 2017 Dear Healthcare Provider, The information contained here may be very important to your practice. Please take a moment to review this document. TEST BULLETIN T-SPOT TB TESTING Please see

More information

Christopher M. Lehman, MD, 1,3 Lori W. Wilson, MT(ASCP), MS, 3 and George M. Rodgers, MD, PhD 1-3. Abstract

Christopher M. Lehman, MD, 1,3 Lori W. Wilson, MT(ASCP), MS, 3 and George M. Rodgers, MD, PhD 1-3. Abstract Coagulation and Transfusion Medicine / D-DIMER FOR THE DIAGNOSIS OF DIC Analytic Validation and Clinical Evaluation of the STA LIATEST Immunoturbidimetric D-Dimer Assay for the Diagnosis of Disseminated

More information

Sysmex Educational Enhancement and Development No

Sysmex Educational Enhancement and Development No SEED Coagulation Sysmex Educational Enhancement and Development No 2 2016 An approach to the bleeding patient The purpose of this newsletter is to provide an overview of the approach to the bleeding patient

More information

FIGURE 1. Coagulation cascade. a = activated factor; Ca = calcium; PL = phospholipid. Adapted from Biochemistry, 2 with permission from American Chemi

FIGURE 1. Coagulation cascade. a = activated factor; Ca = calcium; PL = phospholipid. Adapted from Biochemistry, 2 with permission from American Chemi CONCISE REVIEW FOR CLINICIANS PROLONGED PT AND APTT How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults ARIF H. KAMAL, MD; AYALEW

More information

Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A.

Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. UvA-DARE (Digital Academic Repository) Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. Link to publication Citation for published version (APA): Squizzato, A.

More information

Blood platelets play important role in coagulation.

Blood platelets play important role in coagulation. B.N. Bandodkar College of Science, Thane T.Y. B.Sc Paper II Haematology Blood Coagulation / Blood clotting By Dr N.N. Patil Introduction: When blood is shed, it looses its fluidity within few minutes and

More information

Continuing Medical Education

Continuing Medical Education Continuing Medical Education WHY DO HEMOPHILIACS BLEED? B.R. Agarwal Z.E. Currimbhoy Deficiency of coagulation factor VIII (antihemophilic factor) and coagulation factor IX (Christmas factor) result in

More information

coagulation defect of paracetamol-induced hepatic necrosis

coagulation defect of paracetamol-induced hepatic necrosis Gut, 1974, 15, 89-93 A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis B. G. GAZZARD, R. CLARK, V. BORIRAKCHANYAVAT, AND ROGER WILLIAMS From the Liver

More information

A Case of Factor XII Deficiency Which was Found in Recurrent Spontaneous Abortion. Y. S. Nam, I. H. Kim, T. K. Yoon, C. N. Lee and K. Y.

A Case of Factor XII Deficiency Which was Found in Recurrent Spontaneous Abortion. Y. S. Nam, I. H. Kim, T. K. Yoon, C. N. Lee and K. Y. 12 1 A Case of Factor XII Deficiency Which was Found in Recurrent Spontaneous Abortion Y S Nam, I H Kim, T K Yoon, C N Lee and K Y Cha Department of Obstetrics and Gynecology, College of Medicine, Pocheon

More information

Appendix 3 PCC Warfarin Reversal

Appendix 3 PCC Warfarin Reversal Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin

More information

Evaluation Report. Eurolyser PT (INR) test kit (ST0180) on CUBE and smart analysers

Evaluation Report. Eurolyser PT (INR) test kit (ST0180) on CUBE and smart analysers Evaluation Report Eurolyser PT test kit (ST0180) on CUBE and smart analysers Locations Location 1: Eurolyser Diagnostica GmbH Operator: Simone Wieser Date: 30.06.2015 Specimens The specimens used for analysis

More information

Instruments smart solutions & service IGZ Instruments AG Räffelstrasse 32 CH 8045 Zürich

Instruments smart solutions & service IGZ Instruments AG Räffelstrasse 32 CH 8045 Zürich ADP (Adenosine-5 -Diphosphate) 101312 3 x 0.5mL ADP is a lyophilized preparation of adenosine-5 -diphosphate. The working concentration of the reconstituted reagent is 2 x 10-4 M. ADP is for use in routine

More information

Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot

Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot Hemostasis Clo)ng factors and Coagula4on Dr Badri Paudel www.badripaudel.com Hemostasis is defined as a property of circula4on whereby blood is maintained within a vessel and the ability of the system

More information

WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION

WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT ARTICLES OUR STUDY BLEEDING CONTROL 5 POINT MODEL WO NDCLOT The WoundClot Principals for Effective Bleeding Control PRESENTATION Harnessing SCIENCE

More information

TRAUMA RESUSCITATION. Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital

TRAUMA RESUSCITATION. Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital TRAUMA RESUSCITATION Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital First Principles.ATLS/EMST A- Airway and C-spine B- Breathing C- Circulation and Access D- Neurological deficit E- adequate

More information

Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers

Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers Citation: Clin Transl Sci (2016) 9, 176 180; C 2016 ASCPT. All rights reserved doi:10.1111/cts.12398 ARTICLE Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate

More information

Coagulation parameters as predictors of DIC in patients with intact aortic aneurysm

Coagulation parameters as predictors of DIC in patients with intact aortic aneurysm 162/26 2004 Schattauer GmbH Coagulation parameters as predictors of DIC in patients with intact aortic aneurysm M. M. Jeleńska Department of General, Vascular and Transplant Surgery (Head: Prof. Dr. med.

More information

Dispelling myths about coagulation abnormalities in internal medicine

Dispelling myths about coagulation abnormalities in internal medicine Clinical Medicine 2014 Vol 14, No 3: 239 44 CLINICAL PRACTICE Dispelling myths about coagulation abnormalities in internal medicine Author: Jecko Thachil A ABSTRACT The clotting screen is an integral part

More information

Anticoagulants: Agents, Pharmacology and Reversal

Anticoagulants: Agents, Pharmacology and Reversal Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University

More information

laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie.

laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie. laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie. Disclosures Malake Naboulsi declare to meeting attendees that

More information

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate

More information

Biology 2180 Laboratory #3. Enzyme Kinetics and Quantitative Analysis

Biology 2180 Laboratory #3. Enzyme Kinetics and Quantitative Analysis Biology 2180 Laboratory #3 Name Introduction Enzyme Kinetics and Quantitative Analysis Catalysts are agents that speed up chemical processes and the catalysts produced by living cells are called enzymes.

More information

DIC. Bert Vandewiele Fellow Critical Care 23 May 2011

DIC. Bert Vandewiele Fellow Critical Care 23 May 2011 DIC Bert Vandewiele Fellow Critical Care 23 May 2011 Dissiminated Intravascular Coagulopathie 11/3/2011 Dr. Bert Vandewiele 2 Dissiminated Intravascular Coagulopathie = Consumption coagulopathie = Defibrination

More information

Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins

Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes

More information

Save My Exams! The Home of Revision For more awesome GCSE and A level resources, visit us at Heart & Circulation

Save My Exams! The Home of Revision For more awesome GCSE and A level resources, visit us at   Heart & Circulation Heart & Circulation Question Paper 3 Level International A Level Subject Biology Exam Board Edexcel Topic Molecules, Transport and Health Sub-Topic Heart & Circulation Booklet Question paper 3 Time Allowed:

More information

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation

More information

HEME 10 Bleeding Disorders

HEME 10 Bleeding Disorders HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional

More information

DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital

DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital Disseminated intravascular coagulation (DIC) Disseminated

More information

Blood Lecture Test Questions Set 2 Summer 2012

Blood Lecture Test Questions Set 2 Summer 2012 Blood Lecture Test Questions Set 2 Summer 2012 1. Leukocytes are attracted to a site of injury or disease by: a. diapedesis b. chemotaxis c. leukocytosis d. heparin e. leukomotosis 2. Leukocytes leave

More information

Diagnosis of hypercoagulability is by. Molecular markers

Diagnosis of hypercoagulability is by. Molecular markers Agenda limitations of clinical laboratories to evaluate hypercoagulability and the underlying cause for thrombosis what is the INR the lupus anticoagulant and the antiphospholipid antibody syndrome hassouna

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/28736 holds various files of this Leiden University dissertation. Author: Debeij, Jan Title: The effect of thyroid hormone on haemostasis and thrombosis

More information

Recent studies have found that elevated levels of coagulation

Recent studies have found that elevated levels of coagulation Elevated Hemostatic Factor Levels as Potential Risk Factors for Thrombosis Wayne L. Chandler, MD; George M. Rodgers, MD, PhD; Jason T. Sprouse, MD; Arthur R. Thompson, MD, PhD Recent studies have found

More information

SensoLyte Rh110 Cathepsin K Assay Kit *Fluorimetric* Revision#1.2 Last Updated: May 2017 Catalog # Kit Size

SensoLyte Rh110 Cathepsin K Assay Kit *Fluorimetric* Revision#1.2 Last Updated: May 2017 Catalog # Kit Size SensoLyte Rh110 Cathepsin K Assay Kit *Fluorimetric* Revision#1.2 Last Updated: May 2017 Catalog # 72152 Kit Size 100 Assays (96-well plate) Optimized Performance: This kit detects Cathepsin K activity.

More information

Physiology of. The Blood hemostasis. By prof. Israa f. jaafar

Physiology of. The Blood hemostasis. By prof. Israa f. jaafar Physiology of The Blood hemostasis By prof. Israa f. jaafar Learning objectives Understand the Platelet structure and function Explane the Platelet production Understand the phases of hemostasis: vascular

More information

Moath Darweesh. Omar Sami. Saleem Khreisha. 1 P a g e

Moath Darweesh. Omar Sami. Saleem Khreisha. 1 P a g e 7 Moath Darweesh Omar Sami Saleem Khreisha 1 P a g e -First of all, I want to give a quick revision to simplify the whole hemostasis mechanism, it will be much easier here with me. Enjoy (you can skip

More information